Cancer

CytomX Therapeutics – Next Generation of Cancer Treatments

CytomX Therapeutics - Next Generation of Cancer Treatments

Dr. Amy Peterson, MD, President and Chief Operating Officer at CytomX Therapeutics, Inc. discusses its Probody ®  therapeutic platform and pipeline to destroy cancer, differently – designing biologic therapies to preferentially engage and kills cancer cells, not  healthy cells, thanks to an ingenious gatekeeping mechanism that masks a therapeutic’s binding site until it is conditionally activated and removed by conditions common to the tumor microenvironment.  She also talks about the company’s clinical-stage research programs  and their leadership in the growing space of conditional activation therapy in oncology.  

Frequently Asked Questions

What is the main topic discussed in this episode of Health Professional Radio?

This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.

How can healthcare professionals benefit from this information?

Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.

Where can I find more information about Cancer?

For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.

Amy Peterson, M.D. joined CytomX in October 2019 as executive vice president and chief development officer, and was promoted to the position of president and chief operating officer in 2022. Prior to joining CytomX, Dr. Peterson was chief medical officer of immuno-oncology at BeiGene, Ltd. where she created and led a global oncology development organization with direct medical oversight and accountability of seven clinical assets in over 30 global trials in all phases of development in solid tumor indications. Prior to BeiGene, Dr. Peterson was vice president of clinical development at Medivation where she was primarily responsible for the development of enzalutamide (XTANDI ®) and talazoparib (TALZENNA ®) in breast cancer. Previously, Dr. Peterson served as associate group medical director at Genentech, where she was responsible for the development of early stage molecules targeting multiple major pathways in oncology. Prior to joining Genentech, Dr. Peterson was an Instructor of Medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski. She currently serves on the board of The American Society of Clinical Oncology’s (ASCO) Conquer Cancer Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in Internal Medicine at Northwestern Memorial Hospital and Fellowship in Hematology and Oncology at the University of Chicago. Dr. Peterson received her B.A. degree from Wesleyan University.

Last updated: May 19, 2022

Medical Disclaimer

The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.